These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 1838285)

  • 21. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
    Yu SM; Wu TS; Teng CM
    Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro.
    De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA
    Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thromboxane A2 receptor antagonism and synthase inhibition in essential hypertension.
    Ritter JM; Barrow SE; Doktor HS; Stratton PD; Edwards JS; Henry JA; Gould S
    Hypertension; 1993 Aug; 22(2):197-203. PubMed ID: 8340155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The response to thromboxane A2 analogues in human platelets. Discrimination of two binding sites linked to distinct effector systems.
    Takahara K; Murray R; FitzGerald GA; Fitzgerald DJ
    J Biol Chem; 1990 Apr; 265(12):6836-44. PubMed ID: 2139029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual inhibition of thromboxane A2 synthesis and thromboxane A2/prostaglandin endoperoxide receptors by ridogrel: anti-thrombotic effect in vivo in rat mesenteric arteries.
    Bourgain RH; Andries R; Decuyper K; De Clerck F
    J Lipid Mediat; 1991; 3(1):3-11. PubMed ID: 1837488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
    Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM
    J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
    Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M
    J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 1. (+/-)-(3-pyridinylbicycloheptyl)alkanoic acids.
    Bhagwat SS; Gude C; Cohen DS; Lee W; Furness P; Clarke FH
    J Med Chem; 1991 Jun; 34(6):1790-7. PubMed ID: 1829485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Binding characteristics of the new thromboxane A2/prostaglandin H2 receptor antagonist [3H]BAY U 3405 to washed human platelets and platelet membranes.
    Theis JG; Dellweg H; Perzborn E; Gross R
    Biochem Pharmacol; 1992 Aug; 44(3):495-503. PubMed ID: 1387312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Labeling of human platelet plasma membrane thromboxane A2/prostaglandin H2 receptors using SQB, a novel biotinylated receptor probe.
    Komiotis D; Wencel-Drake JD; Dieter JP; Lim CT; Le Breton GC
    Biochem Pharmacol; 1996 Sep; 52(5):763-70. PubMed ID: 8765474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The affinities of prostaglandin H2 and thromboxane A2 for their receptor are similar in washed human platelets.
    Mayeux PR; Morton HE; Gillard J; Lord A; Morinelli TA; Boehm A; Mais DE; Halushka PV
    Biochem Biophys Res Commun; 1988 Dec; 157(2):733-9. PubMed ID: 2974286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT).
    Circulation; 1994 Feb; 89(2):588-95. PubMed ID: 8313547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo.
    De Clerck F; Beetens J; Van de Water A; Vercammen E; Janssen PA
    Thromb Haemost; 1989 Feb; 61(1):43-9. PubMed ID: 2526385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 7-[(1R,2S,3S,5R)-6,6-dimethyl-3-(4- iodobenzenesulfonylamino)bicyclo[3.1.1]hept-2-yl]-5(Z)-heptenoic acid: a novel high-affinity radiolabeled antagonist for platelet thromboxane A2/prostaglandin H2 receptors.
    Naka M; Mais DE; Morinelli TA; Hamanaka N; Oatis JE; Halushka PV
    J Pharmacol Exp Ther; 1992 Aug; 262(2):632-7. PubMed ID: 1386885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
    Hoet B; Arnout J; Deckmyn H; Vermylen J
    Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets.
    Vezza R; Mezzasoma AM; Venditti G; Gresele P
    Thromb Haemost; 2002 Jan; 87(1):114-21. PubMed ID: 11848439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade, combined in one molecule.
    De Clerck F; Beetens J; de Chaffoy de Courcelles D; Vercammen E; Freyne E; Janssen PA
    Prog Clin Biol Res; 1989; 301():567-72. PubMed ID: 2529556
    [No Abstract]   [Full Text] [Related]  

  • 38. 6,6-Disubstituted Hex-5-enoic acid derivatives as combined thromboxane A2 receptor antagonists and synthetase inhibitors.
    Soyka R; Heckel A; Nickl J; Eisert W; Müller TH; Weisenberger H
    J Med Chem; 1994 Jan; 37(1):26-39. PubMed ID: 8289199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The in vitro effect of ridogrel on platelet function in normocholesterolaemic and familial hypercholesterolaemic type IIa subjects.
    Naran NH; Chetty N
    Thromb Res; 1997 Dec; 88(5):399-407. PubMed ID: 9556227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 12-HETE inhibits the binding of PGH2/TXA2 receptor ligands in human platelets.
    Fonlupt P; Croset M; Lagarde M
    Thromb Res; 1991 Jul; 63(2):239-48. PubMed ID: 1837628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.